| Journal |
Year |
Title |
| Journal of Immunotherapy |
2009 |
Engineering and Biological Characterization of VB6-845, an Anti-EpCAM Immunotoxin Containing a T-cell Epitope-depleted Variant of the Plant Toxin Bouganin |
| Cancer Biotherapy & Radiopharmaceuticals |
2009 |
Preclinical Assessment of an Anti-EpCAM Immunotoxin: Locoregional Delivery Provides a Safer Alternative to Systemic Administration |
| |
| Preclinical Safety Evaluation of BioPharmaceuticals Chapter 29 |
2008 |
Preclinical Safety Evaluation of Immunotoxins |
| Current Opinion of Molecular Therapy |
2008 |
VB4-845, a conjugated recombinant antibody and immunotoxin for head and neck cancer and bladder cancer |
| Journal of Drug Design, Development and Therapy |
2008 |
A phase I clinical study of VB4-845: Weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck |
| Medical Oncology |
2008 |
A phase I clinical study of intratumorally administered VB4-845, an anti-epithelial cell adhesion molecule recombinant fusion protein, in patients with squamous cell carcinoma of the head and neck |
| |
| Biochemical and Biophysical Research Communications |
2006 |
A targeted proteomic approach for the identification of tumor-associated membrane antigens using the ProteomeLab™ PF-2D in tandem with mass spectrometry |
| |
| Clinical Cancer Research |
2003 |
A Recombinant Immunotoxin Derived from a Humanized Epithelial Cell Adhesion Molecule-specific Single-Chain Antibody Fragment Has Potent and Selective Antitumor Activity |
| |
| Biotechnology International |
1997 |
Development and Characterization of Pancarcinoma Specific Human Monoclonal Antibody H11 (NOVOMAb-G2) |
